Idenix Pharmaceuticals, Inc. (IDIX) - NASDAQ
IDIX is defunct.
  • Jun. 9, 2014, 12:45 PM
    | Jun. 9, 2014, 12:45 PM
  • Jun. 9, 2014, 9:13 AM
    | Jun. 9, 2014, 9:13 AM | 1 Comment
  • Apr. 7, 2014, 12:45 PM
    | Apr. 7, 2014, 12:45 PM | 2 Comments
  • Mar. 10, 2014, 9:19 AM
    • Shares of Idenix Pharmaceuticals (IDIX) are up almost 17% premarket on no significant news.
    • Consensus revenue estimates for 2014 and 2015 are $1.5M and $7.7M, respectively.
    • 175 mutual funds have positions, down from 198 a year earlier.
    • Three analysts rate the company at least Buy, eight rate it Hold, two rate it Underperform and one rates it Sell.
    | Mar. 10, 2014, 9:19 AM | 1 Comment
  • Feb. 14, 2014, 10:19 AM
    • In its Q4 13F, activist investor Sarissa Capital discloses it has a 5.05M-share (3.3%) stake in Idenix Pharmaceuticals (IDIX +1.8%). Shares initially jumped on the disclosure,  but have quickly given back some of their gains.
    • Last year, Sarissa took part in a successful proxy battle against Vivus. The firm now has Ariad Pharmaceuticals in its sights.
    | Feb. 14, 2014, 10:19 AM
  • Feb. 4, 2014, 5:39 PM
    | Feb. 4, 2014, 5:39 PM
  • Feb. 4, 2014, 5:10 PM
    • Baupost's latest 13D shows a 39.8%, or 53.3M share stake in Indenix Pharmaceuticals (IDIX) vs 35% at last report. Baupost also say's it's engaged management and has been granted observer rights to board meetings.
    • Shares +7.3% AH
    | Feb. 4, 2014, 5:10 PM
  • Jan. 27, 2014, 1:30 PM
    • Five months after upgrading Idenix (IDIX -7.8%) to Market Perform, JMP has downgraded the HCV drug developer back to Underperform.
    • Going into today, Idenix had nearly doubled from the time of JMP's upgrade.
    | Jan. 27, 2014, 1:30 PM | 2 Comments
  • Jan. 6, 2014, 2:09 PM
    • McKesson (MCK -0.1%) upgraded to Strong Buy from Outperform at Raymond James.
    • DaVita (DVA +0.4%) upgraded to Outperform from Market Perform at Raymond James.
    • Idenix Pharmaceuticals (IDIX -0.3%) upgraded to Buy from Neutral at UBS.
    • Abbott Labs (ABT +1.5%) upgraded to Overweight from Equalweight at Morgan Stanley.
    • Medtronic (MDT +2%upgraded to Overweight from Neutral at JPMorgan. Price target is $69.
    • Vertex Pharmaceuticals (VRTX +2.5%) upgraded to Buy from Neutral at UBS.
    • Ocera Therapeutics (OCRX +2.7%) upgraded to Outperform from Market Perform at BMO.
    • Boston Scientific (BSX +3.2%upgraded to Overweight from Equalweight at Morgan Stanley.
    • Exelixis (EXEL +4.6%) upgraded to Overweight from Neutral at Piper.
    • St. Jude Medical (STJ +3.8%) upgraded to Overweight from Equalweight at Morgan Stanley.
    | Jan. 6, 2014, 2:09 PM | 3 Comments
  • Dec. 24, 2013, 11:15 AM
    | Dec. 24, 2013, 11:15 AM
  • Dec. 17, 2013, 12:45 PM
    | Dec. 17, 2013, 12:45 PM
  • Nov. 1, 2013, 12:55 PM
    • Deutsche's Alethia Young thinks the rally in shares of Idenix Pharmaceuticals (IDIX +41%) may be attributable to the upcoming AASLD meeting which begins this weekend.
    • Here's Young: "IDIX has noted that they are not interested in an exclusive arrangement with JNJ or anyone else [but] we would assume that any HCV developer would be interested in a nuke."
    • IDIX's HELIX-1 trial is evaluating the company's NS5A inhibitor, samatasvirin in combination with JNJ's simeprevir.
    • Deutsche has the shares at Hold.
    | Nov. 1, 2013, 12:55 PM
  • Nov. 1, 2013, 12:47 PM
    | Nov. 1, 2013, 12:47 PM
  • Nov. 1, 2013, 11:35 AM
    • Shares of Idenix Pharmaceuticals (IDIX +32.8%) are on-the-move this morning, trading sharply higher on heavy volume.
    • Although there are no readily apparent catalysts for the move, the company did give an HCV pipeline update Wednesday along with its Q3 report.
    • Summary: Enrollment initiated for IDX21437 Phase 1/2, enrollment complete in HELIX-1 (that's the samatasvir/ simeprevir/ ribavirin GT1b and GT4 trial) with SVR4 data expected in Q4.
    • Also of note, IDIX said its cash "will be sufficient to sustain its operations through December 2014." (PR)
    | Nov. 1, 2013, 11:35 AM
  • Oct. 16, 2013, 10:17 AM
    • Edwards Lifesciences (EW +1.9%) raised to Buy from Neutral at Citi.
    • Idenix Pharmaceuticals (IDIX +2.7%) upgraded to Neutral from Underperform at Credit Suisse.
    • Achillion (ACHN +0.7%) downgraded to Neutral from Outperform at Credit Suisse.
    • Geron (GERN +20.5%) initiated at Buy at MLV. Price target is $6.50.
    | Oct. 16, 2013, 10:17 AM | 1 Comment
  • Oct. 8, 2013, 3:04 PM
    • Johnson & Johnson's (JNJ -0.7%) purchase of GlaxoSmithKline's (GSK -1%) hepatitis C treatment sends Idenix Pharmaceuticals (IDIX -15.8%) tumbling. JNJ bought the rights to a compound in a class of drugs called non-structural 5A protein inhibitors, suggesting it's close to ending its partnership with Identix based on its hep C therapies, including the NS5A drug samatasvir, says Wells' Brian Abrahams.
    • "Hep C battle lines (are) being drawn,” says Abrahams. Idenix’s drug “will need a new partner.”
    | Oct. 8, 2013, 3:04 PM | 4 Comments
Company Description
Idenix Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and Europe.
Sector: Healthcare
Industry: Biotechnology
Country: United States